Photoderm AR SPF50+

• High-technology sun protection (SPF 50+) (1) reinforced against UVA rays. (2)
• Very water resistant (1)
• Cellular BIOprotection® patent: protection against cells alteration and oxidative stress
• Reduction of photo-induced erythema (3)
• Reduction of clinical signs caused by rosacea (4)
• ROSACTIV® patent which significantly inhibits the secretion of VEGF by keratinocytes (-75%**)(5) leading to the reduction of vasodilation responsible for redness.

Very good cutaneous and ocular tolerance (6)- For face & body - Non-comedogenic (7)- Penetrates quickly - Non-sticky - Non-greasy (6)

Clinically tested on patients with sensitive and reactive skin suffering from rosacea grades I and II, couperosis or redness on face

* p< 0.05, Student T, after 1 month
**p<0.001, Student test

1.Evaluation of solar protection factor (SPF) and Water Resistance Proprieties (by CTFA method) of Photoderm AR – 10 volunteer

2.Evaluation of UVA Protection Factor of Photoderm AR – 10 volunteer

3.Evaluation of soothing effect of Photoderm AR with actives and photoprotectives filters versus placebo – 10 volunteers

4.Clinical and dermoscopic evaluation of Photoderm AR in rosacea patients, comparative and single blind study – 20 subjects (aged 36 to 74 years) with stage I and II rosacea, before and after exposure to narrow and UVB. Italy. 2020.

5.In vitro tests. Activity of Rosactiv® patent on the secretion of VEGF by normal human keratinocytes stimulated by TNF-α

6.User test on Photoderm AR – 20 volunteers (aged 20- 64 years) with face skin prone to couperosis, sensitive / reactive, and used to high solar protection factor products applications on face.

7.Usage test and assessment of non-comedogenicity of Photoderm AR – 21 volunteers (aged 19-65 years) with combination to oily skin and sensitive, fair to very fair skin, and redness on face. France.

> CLINICAL RESULTS

SOLAR PROTECTION INDEXES
Evaluating Photoderm AR properties, it can be considered as:

• A very high solar protection (SPF >50)(1) reinforced against UVA (2)
• Very water resistant (1)
• Photostable: Photoderm AR presents a residual efficacy of 82% (threshold value > 70%) (3)

OTHER PROPERTIES
The ROSACTIV® patent significantly inhibits the secretion of VEGF by keratinocytes (-75%**)(4) leading to the reduction of vasodilation responsible for redness.
After a preventive application of Photoderm AR for 2 days and irradiation for 6 hours, the area treated by Photoderm AR presents a significantly decreased photo-induced erythema versus the non-treated zone or placebo. (5)

After 8 days of application on the face and before each outing, Photoderm AR did not cause tanning or sunburn in the photo-protected areas. (6)

Photoderm AR was applied onto half of the face, on subjects suffering from  rosacea stages I or II (no application on the other half of the face), (7) After 1 month of UVB phototherapy the results demonstrated:

• On the untreated side, there was a significant aggravation of couperosis* and tightness*
• On side of the face protected by Photoderm AR, there was a significant decrease in couperosis* and in tightness*
• The difference between both sides of the face after the UVB sessions is very significant**

Therefore, Photoderm AR protects against skin damage caused by UV rays and improves the vascular and follicular manifestations associated with rosacea. (7)

TOLERANCE
Photoderm AR is very well tolerated on the ocular level and on the cutaneous level even when tested on skin irritated by stripping (8)

 *p<0.05, student Test, after one mont
p<0.001

> PATIENTS FEEDBACKS
More than 90% of patients found that Photoderm AR was easy to spread and quickly absorbed. Skin Is more comfortable and more supple (8)

1.Evaluation of solar protection factor (SPF) and Water Resistance Proprieties (by CTFA method) of Photoderm AR – 10 volunteers

2.Evaluation of UVA Protection Factor of Photoderm AR – 10 volunteers  

3.Evaluation of the photostability of Photoderm AR calculated from the SPF before and after irradiation.

4.In vitro tests. Activity of Rosactiv® patent on the secretion of VEGF by normal human keratinocytes stimulated by TNF-α

5.Evaluation of soothing effect of Photoderm AR with actives and photoprotectives filters versus placebo – 10 volunteers.

6.Evaluation of Photoderm AR in prevention of harmful effects due to solar exposition in subjects prone to couperosis – open multicentric trial – 10 subjects (aged 34 - 65 years). France. 2022

7.Clinical and dermoscopic evaluation of Photoderm AR in rosacea patients, comparative and single blind study – 20 subjects (aged 36 to 74 years) with stage I and II rosacea, before and after exposure to narrow and UVB. Italy. 2020.

8.User test on Photoderm AR – 20 volunteers (aged 20- 64 years) with the face skin prone to couperosis, sensitive / reactive, and used to high solar protection factor products applications on face.